BridgeMD
Tests treatment safety and results for Alopecia Areata
Official title A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
ClinicalTrials.gov ID: NCT07023302
What this study is testing
What is Upadacitinib?
Upadacitinib is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for alopecia areata.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body.
- Phase 3: a large, late-stage study
- Time commitment: about 104 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 63
You may be able to join if
- Participant is judged to be in good health as determined by the Principal Investigator, based upon the results of the Screening assessments and...
- Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score \>= 25 (\>= 25% scalp hair loss) at Screening and Baseline.
- Current episode of AA of less than 8 years.
You likely can't join if
- Current diagnosis of primarily diffuse type of AA.
- Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male...
- Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the...
- Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior...
- Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable...
The study team makes the final eligibility decision.
Where it's taking place
- Nagoya, Aichi-ken, Japan
- Kurume-shi, Fukuoka, Japan
- Kahoku-gun, Ishikawa-ken, Japan
- Ebina-shi, Kanagawa, Japan
- Miyagi-gun, Miyagi, Japan
- Sendai, Miyagi, Japan
- Niigata, Niigata, Japan
- Osaka, Osaka, Japan
- Hamamatsu, Shizuoka, Japan
- Mitaka-shi, Tokyo, Japan
- Shinjuku-ku, Tokyo, Japan
- Ube, Yamaguchi, Japan
- Tokyo, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 104 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 63 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nagoya, Aichi-ken, Japan; Kurume-shi, Fukuoka, Japan; Kahoku-gun, Ishikawa-ken, Japan; Ebina-shi, Kanagawa, Japan; Miyagi-gun, Miyagi, Japan; Sendai, Miyagi, Japan and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.